Search Results - "Catteau, A"

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study by Pagès, F, André, T, Taieb, J, Vernerey, D, Henriques, J, Borg, C, Marliot, F, Ben Jannet, R, Louvet, C, Mineur, L, Bennouna, J, Desrame, J, Faroux, R, Kirilovsky, A, Duval, A, Laurent-Puig, P, Svrcek, M, Hermitte, F, Catteau, A, Galon, J, Emile, J-F

“…The Immunoscore (IS), which prognostically classifies stage I-III colon cancer (CC) patients, was evaluated in the International Duration Evaluation of…”
Get full text

Leptin and its potential interest in assisted reproduction cycles by Catteau, A, Caillon, H, Barrière, P, Denis, M G, Masson, D, Fréour, T

“…Leptin, an adipose hormone, has been shown to control energy homeostasis and food intake, and exert many actions on female reproductive function. Consequently,…”
Get full text

Impact of the Immunoscore® assay on adjuvant chemotherapy decision making in patients with resected stage II-III colon cancer: A prospective, multicenter study (PROSCORE) by Malka, D., Mollevi, C., Hermitte, F., Catteau, A., Lachaux, N., Jouffroy, C.

Get full text

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors by Soria, J-C, Cortes, J, Massard, C, Armand, J-P, De Andreis, D, Ropert, S, Lopez, E, Catteau, A, James, J, Marier, J-F, Beliveau, M, Martell, R E, Baselga, J

Get full text

Corrigendum to ‘Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study’: Annals of Oncology 2020; Volume 31: 921-929 by Pagès, F., André, T., Taieb, J., Vernerey, D., Henriques, J., Borg, C., Marliot, F., Ben Jannet, R., Louvet, C., Mineur, L., Bennouna, J., Desrame, J., Faroux, R., Kirilovsky, A., Duval, A., Laurent-Puig, P., Svrcek, M., Hermitte, F., Catteau, A., Galon, J., Emile, J-F.

Get full text

Review: Why screen for severe combined immunodeficiency disease? by Thomas, C., Hubert, G., Catteau, A., Danielo, M., Riche, V.P., Mahlaoui, N., Moshous, D., Audrain, M.

“…Newborn screening for severe combined immunodeficiency (SCID) is now routinely performed in many countries across Europe and around the world. The number of…”
Get full text

Genomic grade adds prognostic value in invasive lobular carcinoma by Metzger-Filho, O., Michiels, S., Bertucci, F., Catteau, A., Salgado, R., Galant, C., Fumagalli, D., Singhal, S.K., Desmedt, C., Ignatiadis, M., Haussy, S., Finetti, P., Birnbaum, D., Saini, K.S., Berlière, M., Veys, I., de Azambuja, E., Bozovic, I., Peyro-Saint-Paul, H., Larsimont, D., Piccart, M., Sotiriou, C.

“…The prognostic value of histologic grade (HG) in invasive lobular carcinoma (ILC) remains uncertain, and most ILC tumors are graded as HG2. Genomic grade (GG)…”
Get full text

Semantic memory assessment in 15 patients with amyotrophic lateral sclerosis by Hervieu-Bègue, M., Rouaud, O., Graule Petot, A., Catteau, A., Giroud, M.

“…A total of 30 to 50% of amyotrophic lateral sclerosis patients suffer from cognitive disorders. The aim of the study is to characterize these disorders and to…”
Get full text

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors by Soria, J.-C., Cortes, J., Massard, C., Armand, J.-P., De Andreis, D., Ropert, S., Lopez, E., Catteau, A., James, J., Marier, J.-F., Beliveau, M., Martell, R.E., Baselga, J.

“…We studied the safety, tolerability, and recommended dose of BMS-599626, an orally bioavailable inhibitor of the human epidermal growth factor receptor (HER)…”
Get full text

Leptomeningeal dissemination after ethmoidal sinus adenocarcinoma surgery: a rare complication by Béjot, Y, Catteau, A, Hervieu, M, Giré, P, Caillier, M, Bénatru, I, Osseby, G-V, Soichot, P, Moreau, T, Giroud, M

“…Although rare, adenocarcinoma is the most frequent neoplasm of the ethmoid sinus and must be regarded as an occupational disease secondary to chronic wood dust…”
Get full text

SO-28 FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable mCRC patients: Updated and overall survival results of the phase II randomized AtezoTRIBE study by Antoniotti, C., Rossini, D., Pietrantonio, F., Salvatore, L., Marmorino, F., Ambrosini, M., Lonardi, S., Bensi, M., Moretto, R., Tamberi, S., Toma, I., Passardi, A., De Grandis, M., Conca, V., Palermo, M., Cappetta, A., Catteau, A., Boni, L., Galon, J., Cremolini, C.

Get full text

147TiPImpact of the Immunoscore® assay on adjuvant chemotherapy decision making in patients with resected stage II-III colon cancer: A prospective, multicenter study (PROSCORE) by Malka, D, Mollevi, C, Hermitte, F, Catteau, A, Lachaux, N, Jouffroy, C

Get full text

336P Prognostic and predictive value of Immunoscore in stage III colorectal cancer in the combined SCOT and IDEA-HORG studies by Church, D., Hay, J., Sansom, O.J., N. Maka, Oien, K.A., Iveson, T.J., Saunders, M.P., Edwards, J., Harkin, A., Boukovinas, I., Moustou, E., Messaritakis, I., Chondrozoumaki, M., Georgoulias, V., Boquet, I., Pages, F., Catteau, A., Galon, J., Kelly, C., Souglakos, I.

Get full text

Flaviviruses and apoptosis regulation by Catteau, A, Courageot, M P, Desprès, P

Get more information

A population and family study of CYP1A2 using caffeine urinary metabolites by CATTEAU, A, BECHTEL, Y. C, POISSON, N, BECHTEL, P. R, BONAÏTI-PELLIE, C

“…CYP1A2 is a cytochrome P450 which is inducible by polycyclic aromatic hydrocarbons. This induction could be mediated via the Ah locus, which encodes a…”
Get full text

Corrections to “Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors” by Soria, J.-C., Cortes, J., Massard, C., Armand, J.-P., De Andreis, D., Ropert, S., Lopez, E., Catteau, A., James, J., Marier, J.-F., Beliveau, M., Martell, R.E., Baselga, J.

Get full text

491P Neoadjuvant nivolumab in early stage colorectal cancer by Avallone, A., De Stefano, A., Pace, U., Catteau, A., Di Gennaro, E., Tatangelo, F., Boquet, I., Cassata, A., Costantini, S., De Franciscis, S., Collina, F., Zanaletti, N., Vitagliano, C., Granata, V., Giannarelli, D., Lastoria, S., Ascierto, P.A., Galon, J., Delrio, P., Budillon, A.

Get full text

Corrigendum to ‘Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study’ by Pagès, F., André, T., Taieb, J., Vernerey, D., Henriques, J., Borg, C., Marliot, F., Ben Jannet, R., Louvet, C., Mineur, L., Bennouna, J., Desrame, J., Faroux, R., Kirilovsky, A., Duval, A., Laurent-Puig, P., Svrcek, M., Hermitte, F., Catteau, A., Galon, J., Emile, J-F.

Get full text

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study††Note: This work was previously presented in part at the 2019 American Society of Clinical Oncology meeting (Abstract 3513) and at the 2020 American Society of Clinical Oncology-GI meeting (Abstract 10) by Pagès, F., André, T., Taieb, J., Vernerey, D., Henriques, J., Borg, C., Marliot, F., Ben Jannet, R., Louvet, C., Mineur, L., Bennouna, J., Desrame, J., Faroux, R., Kirilovsky, A., Duval, A., Laurent-Puig, P., Svrcek, M., Hermitte, F., Catteau, A., Galon, J., Emile, J.-F.

“…The Immunoscore (IS), which prognostically classifies stage I–III colon cancer (CC) patients, was evaluated in the International Duration Evaluation of…”
Get full text

Identification of a C/G polymorphism in the promoter region of the BRCA1 gene and its use as a marker for rapid detection of promoter deletions by CATTEAU, A, XU, C.-F, BROWN, M. A, HODGSON, S, GREENMAN, J, MATHEW, C. G, DUNNING, A. M, SOLOMON, E

“…Reduced expression of BRCA1 has been implicated in sporadic breast cancer, although the mechanisms underlying this phenomenon remain unclear. To determine…”
Get full text